April 16, 2013 at 14:31 PM EDT
VIVUS Announces FDA Approval of Qsymia REMS Modification Allowing Access Through Certified Retail Pharmacies
VIVUS (Nasdaq: VVUS ) today announced that the U.S. Food and Drug Administration (FDA) has approved its amendment and modification to the Risk Evaluation and Mitigation Strategy (REMS) for Qsymia^® (phentermine and topiramate extended-release) capsules CIV. The amendment, submitted in October 2012, allows Qsymia ^ to be dispensed through certified retail pharmacies, in
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here